Mindie H Nguyen1, Huy Trinh2, Son Do3, Thuan Nguyen4, Pauline Nguyen1, Linda Henry1. 1. Stanford University Medical Center, Stanford, Caliornia, USA. 2. San Jose Gastroenterology, San Jose, California, USA. 3. Digestive Health Associates of Texas, Dallas, Texas, USA. 4. Liver and Digestive Consultants, Houston, Texas, USA.
Abstract
OBJECTIVES: Hepatitis C genotype 6 (HCV-GT6) is one of the most prevalent genotypes in Southeast Asia. Ledipasvir and sofosbuvir fixed-dose combination (LDV/SOF FDC) for 12 weeks has been shown to be effective for multiple HCV genotypes including treatment-naïve HCV-6. Our goal was to examine treatment outcomes in a diverse HCV-6 population. METHODS: We prospectively enrolled 60 HCV-GT6 patients at four US centers. Treatment -naïve without cirrhosis patients received open-labeled LDV/SOF FDC orally once a day for 8 weeks; All cirrhotic and/or treatment-experienced patients received LDV/SOF FDC for 12 weeks. The primary outcome was sustained virological response 12 weeks after therapy (SVR12). Secondary outcomes were adverse events (AEs) and/or serious adverse events (SAEs). All patients gave written consent. RESULTS: Overall mean age was 58±10 and 58% were male. All patients were Asian and foreign born. The 8-week group included 20 patients (33.3%) and the 12-week included 40 patients (66.7%). There were 2 (5%) patients with decompensation, 3 with liver cancer (7.5%), and 14 with prior treatment (35%) in the 12-week group. SVR12 was 95.0% for the 8-week group (19/20) and 95.0% for the 12-week group (38/40). AEs included fatigue (5%), insomnia (3.3%), headache (1.7%), and nausea (1.7%); however, all patients completed the intended treatment duration. There were two treatment-unrelated SAEs. CONCLUSIONS: LDV/SOF FDC for 8 or 12 weeks was safe and effective for patients without cirrhosis or prior treatment failure as well as for patients with cirrhosis and/or prior treatment failure, respectively.
OBJECTIVES: Hepatitis C genotype 6 (HCV-GT6) is one of the most prevalent genotypes in Southeast Asia. Ledipasvir and sofosbuvir fixed-dose combination (LDV/SOF FDC) for 12 weeks has been shown to be effective for multiple HCV genotypes including treatment-naïve HCV-6. Our goal was to examine treatment outcomes in a diverse HCV-6 population. METHODS: We prospectively enrolled 60 HCV-GT6 patients at four US centers. Treatment -naïve without cirrhosispatients received open-labeled LDV/SOF FDC orally once a day for 8 weeks; All cirrhotic and/or treatment-experienced patients received LDV/SOF FDC for 12 weeks. The primary outcome was sustained virological response 12 weeks after therapy (SVR12). Secondary outcomes were adverse events (AEs) and/or serious adverse events (SAEs). All patients gave written consent. RESULTS: Overall mean age was 58±10 and 58% were male. All patients were Asian and foreign born. The 8-week group included 20 patients (33.3%) and the 12-week included 40 patients (66.7%). There were 2 (5%) patients with decompensation, 3 with liver cancer (7.5%), and 14 with prior treatment (35%) in the 12-week group. SVR12 was 95.0% for the 8-week group (19/20) and 95.0% for the 12-week group (38/40). AEs included fatigue (5%), insomnia (3.3%), headache (1.7%), and nausea (1.7%); however, all patients completed the intended treatment duration. There were two treatment-unrelated SAEs. CONCLUSIONS: LDV/SOF FDC for 8 or 12 weeks was safe and effective for patients without cirrhosis or prior treatment failure as well as for patients with cirrhosis and/or prior treatment failure, respectively.
Authors: N K T Hlaing; R A Mitrani; S T Aung; W W Phyo; M Serper; A M M Kyaw; A H Bwa; K M Win; K R Reddy Journal: J Viral Hepat Date: 2017-06-10 Impact factor: 3.728
Authors: Patrick Ingiliz; Stefan Christensen; Torben Kimhofer; Dietrich Hueppe; Thomas Lutz; Knud Schewe; Heiner Busch; Günther Schmutz; Malte H Wehmeyer; Christoph Boesecke; Karl-Georg Simon; Florian Berger; Jürgen K Rockstroh; Julian Schulze zur Wiesch; Axel Baumgarten; Stefan Mauss Journal: Clin Infect Dis Date: 2016-08-17 Impact factor: 9.079
Authors: Ira M Jacobson; Eric Lawitz; Edward J Gane; Bernard E Willems; Peter J Ruane; Ronald G Nahass; Sergio M Borgia; Stephen D Shafran; Kimberly A Workowski; Brian Pearlman; Robert H Hyland; Luisa M Stamm; Evguenia Svarovskaia; Hadas Dvory-Sobol; Yanni Zhu; G Mani Subramanian; Diana M Brainard; John G McHutchison; Norbert Bräu; Thomas Berg; Kosh Agarwal; Bal Raj Bhandari; Mitchell Davis; Jordan J Feld; Gregory J Dore; Catherine A M Stedman; Alexander J Thompson; Tarik Asselah; Stuart K Roberts; Graham R Foster Journal: Gastroenterology Date: 2017-04-05 Impact factor: 22.682
Authors: R J Wong; M T Nguyen; H N Trinh; A Huynh; M T Ly; H A Nguyen; K K Nguyen; J Yang; R T Garcia; B Levitt; E da Silveira; R G Gish Journal: J Viral Hepat Date: 2016-09-27 Impact factor: 3.728
Authors: Jane P Messina; Isla Humphreys; Abraham Flaxman; Anthony Brown; Graham S Cooke; Oliver G Pybus; Eleanor Barnes Journal: Hepatology Date: 2014-07-28 Impact factor: 17.425
Authors: Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo Journal: N Engl J Med Date: 2014-04-11 Impact factor: 91.245
Authors: Aoran Luo; Pan Xu; Jin Wang; Zuli Li; Shunli Wang; Xiaoyan Jiang; Hong Ren; Qiang Luo Journal: Medicine (Baltimore) Date: 2019-05 Impact factor: 1.817
Authors: Massimo Giuseppe Colombo; Erkin Isakovich Musabaev; Umed Yusupovich Ismailov; Igor A Zaytsev; Alexander V Nersesov; Igor Anatoliyevich Anastasiy; Igor Alexandrovich Karpov; Olga A Golubovska; Kulpash S Kaliaskarova; Ravishankar Ac; Sanjay Hadigal Journal: World J Gastroenterol Date: 2019-08-07 Impact factor: 5.742
Authors: Leanne McCabe; Ian R White; Nguyen Van Vinh Chau; Eleanor Barnes; Sarah L Pett; Graham S Cooke; A Sarah Walker Journal: Trials Date: 2020-05-18 Impact factor: 2.279
Authors: Ong The Due; Usa Chaikledkaew; Anne Julienne M Genuino; Abhasnee Sobhonslidsuk; Ammarin Thakkinstian Journal: Biomed Res Int Date: 2019-11-11 Impact factor: 3.411